Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Apyx Medical Inc(APYX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for APYX
10/09/2026: APYX (1-star) is currently NOT-A-BUY. Pass it for now.
Apyx Medical is a mid-to-small cap medical device company focused on energy-based cosmetic solutions, primarily its proprietary Helium Plasma-based Renuvion platform. The company's primary strength lies in its unique technology and growing recurring revenue from disposable handpieces used in skin-tightening procedures. Its core growth story centers on increasing the adoption of Renuvion among cosmetic surgeons and expanding its clinical indications. However, investors must consider high execution risks, intense competition from larger device manufacturers, and financial variability as the company matures. This stock is best suited for growth-oriented investors who can tolerate high volatility, with key developments to monitor including clinical adoption rates and regulatory progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company targets high-growth aesthetic markets but faces execution risks and significant competition. |
| Momentum investor | Weak fit | Current trends do not consistently support a strong momentum signal for the stock. |
| Value investor | Weak fit | The lack of consistent profitability makes traditional value metrics difficult to apply. |
| Dividend investor | Weak fit | The company does not pay dividends, prioritizing capital reinvestment. |
| Low-risk investor | Weak fit | The small-cap nature and operational volatility create high risk for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap medical device stocks often experience sharp price swings based on news or sentiment. |
| Valuation risk | Medium / high | Future growth expectations are often baked into the stock price, leaving little room for error. |
| Competition risk (Aesthetic Devices) | High | The company competes with much larger players like InMode and Medtronic for doctor adoption. |
| Business quality | Medium | While the technology is proprietary, the business model is still maturing in terms of profitability. |
| Dividend income | Low / none | The company offers no income component for investors. |
| Execution risk | Medium / high | Success depends on the ongoing adoption of Renuvion by surgeons in a competitive market. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -33.44% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/09/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 109.10M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 137.8K shares | Beta 1.45 | 52 Weeks Range 2.32 - 5.08 | Updated Date 10/11/2026 |
52 Weeks Range 2.32 - 5.08 | Updated Date 10/11/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.2 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Advanced Energy | Renuvion system sales and recurring revenue from single-use disposable handpieces. | The company makes money by selling the machine once and then selling disposable parts every time it is used. |
| OEM/Electrosurgical | Traditional generators, electrodes, and accessories sold to other medical device firms. | This is the legacy, slower-growth segment providing steady but lower-margin income. |
| Geographic Sales | Primary revenue concentration in the United States with growing international distribution efforts. | Sales are currently US-centric, meaning success depends heavily on the domestic aesthetic market. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 72.46 | Enterprise Value 136.28M | Price to Sales(TTM) 1.87 |
Enterprise Value 136.28M | Price to Sales(TTM) 1.87 | ||
Enterprise Value to Revenue 2.33 | Enterprise Value to EBITDA -5.33 | Shares Outstanding 42.12M | Shares Floating 30.50M |
Shares Outstanding 42.12M | Shares Floating 30.50M | ||
Percent Insiders 13.55 | Percent Institutions 50.58 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.